Frontier IP Group PLC (LON:FIPP) said its portfolio firm Exscientia has entered into a collaboration with US research centre SRI International to expedite the discovery of molecules for a high value oncology target.
The IP investor said the agreement will see the two firms implement a new approach to drug discovery using SRI’s automated synthetic-chemistry system with Exscientia's Centaur Chemist system.
READ: Frontier IP says portfolio firm Molendotech raises funds to accelerate development of bacteria tests
Exscientia uses artificial intelligence (AI) to design molecule compounds that can then be used to accelerate drug discovery.
"The opportunity to apply AI drug design through our Centaur Chemist system with SynFini automated chemistry offers an exciting opportunity to accelerate drug discovery timelines through scientific innovation and automation", Exscientia chief executive Andrew Hopkins said in a statement.
Frontier IP owns a 2.3% stake in Exscientia.